Obstetric and perinatal outcomes in parturients with active SARS-CoV-2 infection during labor and delivery: a retrospective cohort study

Rita Zlatkin¹,²*, Sarah Dollinger¹,²†, Chen Jacoby¹,², Anat Shmueli¹,², Shiri Barbash-Hazan¹,², Rony Chen¹,², Arnon Wiznitzer¹,² and Eran Hadar¹,²

Abstract

Background: The COVID-19 pandemic is an ongoing global healthcare crisis that negatively affects pregnant women. Although patients with an acute infection during pregnancy have been widely studied, information regarding labor and delivery while infected is sparse. The aim of the study was to ascertain maternal, obstetrical, and perinatal outcomes of women who gave birth while infected with SARS-CoV-2.

Methods: Patients diagnosed with COVID-19 during pregnancy at a tertiary medical center in 4/20–2/21 were identified by a retrospective database search. Those with an active intrapartum SARS-CoV-2 infection were compared with those who recovered at least 10 days before labor and delivery.

Results: Of the 176 women included in the study, 84 had a SARS-CoV-2 infection at the time of delivery and 92 had recovered from the infection. There was no statistically significant between-group difference in mean gestational age at delivery (39 weeks for both, \( p = 0.71 \)) and overall rate of cesarean delivery (26.2% vs 17.4%, respectively, \( p = 0.35 \)) or non-elective cesarean delivery (10.7% vs 4.3%, respectively, \( p = 0.48 \)). In the active-infection group, the rate of severe disease was 2.4%, and of critical disease (with intensive care unit admission, mechanical ventilation, and ECMO), 3.6%, compared to zero for both in the recovered group. No differences were found between the groups in adverse perinatal outcomes.

Conclusion: Delivery is safe and feasible in women with active SARS-CoV-2 infection. Nevertheless, we found a non-significant trend for more severe disease and for cesarean delivery and urgent cesarean delivery (for COVID-19-related indications) in women with an intrapartum SARS-CoV-2 infection.

Keywords: SARS-CoV-2, COVID-19, Pregnancy, Delivery, Neonatal outcomes

Introduction

The coronavirus disease 2019 (COVID-19) is caused by a single-stranded RNA virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. The World Health Organization declared the COVID-19 outbreak a pandemic in March 2020. It was assumed early on that, like for other infections due to respiratory viruses and related coronavirus strains, pregnant women were...
more vulnerable to SARS-CoV-2 infection and at higher risk of severe disease and complications than the general population [2, 3]. Investigations regarding the effect of COVID-19 infection on maternal and fetal outcomes are still ongoing [4]. Of note, there are several reports of higher rates of admission to intensive care units (ICU), preterm birth, cesarean delivery, and preeclampsia in SARS-CoV-2-infected women [5–10]. Furthermore, despite the many studies on pregnancy and SARS-CoV-2 infection, the literature on parturients with an active infection during delivery is sparse. Data are lacking on the potential impact of the acute infection, or the isolated environmental setting, on different aspects of the delivery process, mainly the mode of delivery, and possibly other outcome factors.

The aim of the present study was to examine maternal, obstetrical, and perinatal outcomes of women with an active SARS-CoV-2 infection at the time of delivery compared to patients who recovered from COVID-19 during pregnancy. The composition of the control group was based on a previous study by Fan et al. [11] which found no adverse or neonatal effects in COVID-19-recovered parturients.

Methods
Study population
All pregnant women who gave birth at a tertiary medical center between April 2020 and February 2021 and were infected with COVID-19 during pregnancy were identified by retrospective search of the hospital’s electronic database. The cohort was divided into two groups: those who tested positive for SARS-CoV-2 up to 10 days prior to delivery and with those who had recovered from the infection by the time of delivery.

Setting
The intrapartum setting for women who are acutely infected with SARS-CoV-2 is significantly different from that of other parturients. They give birth in a positively pressured delivery room without escorts and are obligated to wear a disposable non-woven face mask. Each patient is supervised by a dedicated midwife who is present in the COVID-designated delivery room or observed via a sound and video monitor by the delivery room medical staff. All caregivers who are in close contact with the patient are obligated to use personal protective equipment, including gloves, isolation gown, N95 filtering face-piece, respirator, and face shield.

Definitions
The diagnosis of SARS-CoV-2 infection (Alpha and Delta variants) was based on a positive result of real-time reverse transcriptase polymerase-chain-reaction (RT-PCR) assay of a nasopharyngeal swab specimen (Seegene, Songpa-gu, South Korea). Pregnant women in our center were routinely screened for SARS-CoV-2 if they were in active labor, admitted to the hospital for any reason, quarantined due to exposure to a known COVID-19 patient, and/or had signs or symptoms related to COVID-19. All neonates born to SARS-CoV-2-positive parturients were tested for the virus at 24 and 48 h after birth. Our institution’s policy was to recommend for separation between the mother and neonate after birth in order to prevent neonatal infection, however it was not mandatory.

Recovery from COVID-19 was defined according to the criteria of the Israel Ministry of Health [12]: at least 10 days had passed since the initial positive test (or borderline-positive test with a confirmatory PCR result) and the patient had had none of the following symptoms for at least 3 days: fever ≥38 °C, dyspnea or cough or any other respiratory symptom that did not subside, vomiting, and diarrhea.

The severity of COVID-19 disease was ascertained according to the criteria of Wu et al. [13], as follows: mild – any symptoms related to COVID-19; severe – tachypnea (respiratory rate >30), peripheral oxygen saturation less than 94%, and/or significant lung infiltrates; critical – respiratory failure, septic shock, or mutiple organ dysfunction.

Grand multiparity was defined as parity equal to or greater than five. Preterm birth was defined as delivery before 37 gestational weeks. Birthweight percentiles were calculated using a nationally accepted, gender-specific, reference growth curve [14]. Large for gestational age (LGA) was defined as birthweight above the 90th percentile for gestational age, and small for gestational age (SGA), defined as birthweight below the 10th percentile for gestational age.

For the present study, we documented the lowest peripheral oxygen saturation level measured during hospitalization and blood tests were performed throughout the peripartum. We present the highest or lowest laboratory values according to clinical relevance. The standard cutoffs of our institution were used for all hematological and biochemical parameters.

Antepartum and/or postpartum treatment for COVID-19 consisted of a prophylactic dose of low-molecular-weight heparin (LMWH), alone for hospitalized symptomatic patients and combined with dexamethasone 6 mg daily for 10 days or until discharge for patients with severe disease.

Data collection
Data were retrieved from the hospital’s comprehensive computerized maternal and neonatal medical records,
including records from the emergency room triage, delivery room, maternal–fetal hospitalization, and neonatal nursery or NICU. The collected data included maternal demographics, medical and obstetrical background, antepartum pregnancy follow-up, SARS-CoV-2 test results, COVID-19 clinical parameters and complications, hematological and biochemical test results in the peripartum period, peripartum and postpartum treatment for COVID-19, and obstetrical and perinatal outcomes.

Outcome measures
The primary outcome measure of the study was mode of delivery. Secondary outcomes were maternal SARS-CoV-2 infection characteristics (disease severity, ICU admission and mechanical ventilation), preterm birth, perinatal complications (low Apgar score, NICU admission, and neonatal acidemia defined as umbilical cord pH < 7.2) and neonatal SARS-CoV-2 infection.

Statistical analysis
Data analysis was performed with Statistical Analysis Software version 9.4 (SAS, Cary, NC, USA). Data are presented as median and interquartile range (IQR). Continuous variables were compared using the general linear model. Chi-square and Fisher’s exact tests were used for categorical variables, as appropriate. Differences were considered significant when p-value was < 0.05.

Ethics
The study was approved by the Institutional Review Board of Rabin Medical Center (approval no. 331–20-RMC). Informed consent was waived due to the study’s retrospective design by the Institutional Review Board of Rabin Medical Center. I confirm that all methods were carried out in accordance with all relevant guidelines and regulations.

Results
A total 176 women met the inclusion criteria: 84 were diagnosed with active intrapartum SARS-CoV-2 infection and 92 had recovered from COVID-19 by the time of labor and delivery. There were no significant between-group differences in baseline demographic and clinical characteristics, as shown in Table 1.

The characteristics of the SARS-CoV-2 infection in the two groups are described in Table 2. Women in the active-infection group were diagnosed at a significantly more advanced gestational age than the recovered group (38.5 vs. 29 gestational weeks, respectively. p < 0.0001)

| Table 1 Clinical and pregnancy characteristics of pregnant women with COVID‑19 with or without active disease at delivery |
|---------------------------------------------------------------|
| Clinical and pregnancy characteristics | COVID-19- recovered patients | COVID-19-active patients | p-value |
| Maternal age (years) | 30 (17–45) | 30 (20–44) | 0.965 |
| Body mass index (kg/m²)* | 24.4 (17.9–40.1) | 23.5 (17.3–41) | 0.754 |
| Gravidity | 3 (1–14) | 3 (1–12) | 0.761 |
| Parity | 1.5 (0–10) | 2 (0–9) | 0.913 |
| Nulliparity | 26 (28.26%) | 22 (26.19%) | 0.943 |
| Multiparity | 10 (10.87%) | 10 (11.9%) | 0.943 |
| Previous cesarean delivery | 14 (15.22%) | 14 (16.67%) | 0.839 |
| Coexisting medical diseases | | | |
| Asthma | 2 (2.15%) | 1 (1.2%) | 1 |
| Inflammatory bowel disease | 3 (3.26%) | 0 (0%) | 0.247 |
| Diabetes mellitus | 3 (3.26%) | 2 (2.38%) | 1 |
| Thyroid disease | 8 (8.7%) | 2 (2.38%) | 0.103 |
| Chronic hypertension | 0 (0%) | 1 (1.19%) | 0.477 |
| Anxiety disorder | 3 (3.26%) | 2 (2.38%) | 1 |
| Antiphospholipid antibodies syndrome | 2 (2.17%) | 0 (0%) | 0.498 |
| Chronic medication use | 16 (17.39) | 8 (9.52) | 0.186 |
| Mode of conception | | | |
| Spontaneous | 87 (94.57%) | 79 (94.05%) | 0.724 |
| Assisted reproduction | 5 (5.43%) | 3 (3.57%) | 0.724 |
| Gestational diabetes mellitus | 13 (14.13%) | 15 (17.86%) | 0.541 |
| Hypertensive disorders in pregnancy | 2 (2.17%) | 2 (2.38%) | 0.134 |

Values are presented as median (range) for continuous variables and as n (%) for categorical variables.
and were less symptomatic at the time of initial SARS-CoV-2 diagnosis (33.33% vs. 57.74%, \( p < 0.001 \)). The most common symptoms in the active-infection group were cough (19.05%), malaise (13.1%), and fever (9.52%), and in the recovered group, malaise (38.02%), cough (21.12%) and anosmia/ageusia (18.30%). There was no difference in median peripheral oxygen saturation between the groups. Peripheral oxygen saturation was less than 94% in 6% of the active-infection group but in none of the women in the recovered group \( (p = 0.14) \). The active-infection group also had a significantly higher rate of hospital admission for COVID-19 (9.52% vs. 2.17% in the recovered group, \( p = 0.04 \)), and ICU admission (3.6% vs 0, \( p = 0.1 \)). Three patients in the active-infection group required mechanical ventilation followed by extracorporeal membrane oxygenation (ECMO), whereas none of the patients in the recovered group required these measures (3.6% vs 0, \( p = 0.1 \)). The active-infection group was also characterized by a significantly higher rate of mild COVID-19 disease (27.38% vs. 57.74% in the recovered group, \( p = 0.002 \)), and significantly higher rates of severe and critical disease (2.38% vs 0 and 3.60% vs 0, respectively, \( p = 0.1 \) for both).

The laboratory test results in the two groups are presented in Table 3. No significant between-group difference was noted in white blood cell count. The active-infection group had higher rates of lymphopenia (21.43% vs. 3.5%, \( p = 0.003 \)) and thrombocytopenia (34.52% vs. 17.85%, \( p = 0.035 \)). International normalized ratio and fibrinogen levels were similar in the two groups, as were levels of liver enzymes (aspartate aminotransferase and alanine aminotransferase), creatinine, lactate dehydrogenase, and C-reactive protein. Median D-dimer level in the active-infection group was 2530 ng/mL (range 825–50,422); 14.29% of patients had a D-dimer level of \( \geq \) 3300 ng/mL. D-dimer was not tested in women in the recovered group.

Table 4 shows the obstetric and neonatal outcomes. There was no significant between-group difference in mode of delivery. Compared to the recovered group, the active-infection group had comparable rates of cesarean delivery (26.19% vs. 17.39%, \( p = 0.35 \)) and of non-elective cesarean delivery (10.71% vs. 4.34%, \( p = 0.48 \)). The indications for non-elective cesarean delivery in the active-infection groups were non-reassuring fetal heart rate in 5 patients, dysfunctional labor in 1, and need for cesarean

| COVID-19 characteristics | COVID-19-recovered patients | COVID-19-active patients | \( p \)-value |
|-------------------------|----------------------------|--------------------------|-------------|
| Gestational age at diagnosis (weeks) | 29 (9–39) | 38.5 (25–41) | <0.0001 |
| Symptomatic COVID-19* | 41 (57.74%) | 28 (33.33%) | <0.001 |
| Symptoms* | | | |
| Malaise | 27 (38.02%) | 11 (13.10%) | <0.001 |
| Cough | 15 (21.12%) | 16 (19.05%) | 0.84 |
| Anosmia and/or ageusia | 13 (18.30%) | 5 (5.95%) | 0.02 |
| Fever | 12 (16.90%) | 8 (9.52%) | 0.23 |
| Dyspnea | 12 (16.90%) | 4 (4.76%) | 0.01 |
| Sore throat | 5 (7.04%) | 2 (2.38%) | 0.24 |
| Gastrointestinal | 8 (11.26%) | 2 (2.38%) | 0.04 |
| Oxygen saturation (%)b | 98 (94–100) | 98 (82–100) | 0.78 |
| < 94% | 0 (0%) | 5 (6.0%) | 0.14 |

**COVID-19 severity**

| Mild | 41 (57.74%) | 23 (27.38%) | 0.002 |
| Severe | 0 (0%) | 2 (2.38%) | 0.50 |
| Critical | 0 (0%) | 3 (3.60%) | 0.25 |
| Hospitalization | 2 (2.17%) | 8 (9.52%) | 0.04 |
| ICU admission | 0 (0%) | 3 (3.60%) | 0.10 |
| Invasive ventilation | 0 (0%) | 3 (3.60%) | 0.10 |
| ECMO | 0 (0%) | 3 (3.60%) | 0.10 |

Values are presented as median (range) for continuous variables and as n(%) for categorical variables.

**Abbreviations:** ICU Intensive care unit, ECMO Extracorporeal membrane oxygenation

\( a \) Data were missing for 21 women in the recovered group

\( b \) Data were missing for 68 women in the recovered group and 47 women in the active-infection group.
delivery because of severe COVID-19 in 3. Indications in the recovered group were nonreassuring fetal heart rate in 3 patients and dysfunction labor in 1. The difference in the rate of non-reassuring heart failure between the groups was not statistically significant ( \( p = 0.48 \)). In the 5 of the 9 women in the active-infection group who underwent non-elective cesarean delivery (55.55%), the indication was unrelated to the COVID-19 disease status.

No significant differences were found between the active-infection and recovered groups in gestational age at delivery (39 weeks in both, \( p = 0.71 \)), rate of preterm delivery (10.87% vs. 8.33%, respectively, \( p = 0.61 \)), and rate of induction of labor (18.48% vs. 20.24%, respectively, \( p = 1 \)). Postpartum treatment with LMWH alone or with dexamethasone was significantly more common in the active-infection group (76.19% vs. 10.87%, \( p < 0.001 \)), but antepartum treatment rates in the two groups were comparable for both drugs. There was no between-group difference in median length of hospitalization.

Comparison of perinatal outcomes between the groups yielded no significant difference in birthweight, birthweight percentile, rate of SGA infants, rate of 1-min and 5-min Apgar score < 7, median umbilical cord pH, and rate of NICU admission. SARS-CoV-2 test was positive in 6 neonates in the active-infection group and in none of the neonates in the recovered group (7.14% vs. 0%, \( p < 0.001 \)).

**Discussion**

In the present study, we compared women with an active intrapartum SARS-CoV-2 infection with women who had contracted SARS-CoV-2 infection during pregnancy but recovered by the time of delivery. There were no statistically significant differences between the groups in

### Table 3  Peripartum blood analysis in pregnant women with or without active disease at delivery

| Blood parameters                  | COVID-19- recovered patients \( N = 92 \) | COVID-19- active patients \( N = 84 \) | \( p \)-value |
|-----------------------------------|------------------------------------------|---------------------------------------|--------------|
| WBC (K/micL),\(^a\) highest measured | 12.35 (7.33–20.4)                        | 10.2 (5.69–21.7)                      | 0.0064       |
| WBC \( \geq 15 \) K/micL           | 10 (17.85%)                              | 8 (9.52%)                             | 0.02         |
| Lymphocytes (K/micL),\(^a\) lowest measured | 1.7 (0.6–3.7)                        | 1.3 (0.3–3.6)                        | <0.0001      |
| Lymphocytes < 1 K/micL            | 2 (3.5%)                                 | 18 (21.43%)                           | 0.003        |
| Hemoglobin (g/dL), lowest measured | 11.4 (6.8–14.1)                       | 10.9 (6.2–13.6)                      | 0.09         |
| Hemoglobin < 10 g/dL              | 15 (26.78%)                              | 23 (27.38%)                           | 1            |
| Platelets (K/micL),\(^a\) lowest measured | 199.5 (85–356)                       | 161 (27–352)                          | <0.001       |
| Platelets < 150 K/micL            | 10 (17.85%)                              | 29 (34.52%)                           | 0.03         |
| INR, highest measured\(^b\)       | 0.95 (0.90–0.99)                         | 0.97 (0.86–1.23)                     | 0.08         |
| INR > 1.1                         | 0 (0%)                                   | 6 (7.14%)                             | 0.57         |
| Fibrinogen (mg/dL), lowest measured\(^c\) | 640.5 (193–833)                   | 587 (156–837)                        | 0.062        |
| Fibrinogen < 200 mg/dL            | 5 (5.55%)                                | 2 (2.77%)                             | 0.52         |
| AST (U/L), highest measured\(^d\) | 30 (15–143)                              | 26 (15–178)                           | 0.96         |
| AST > 31 mg/dl                    | 2 (33.33%)                               | 16 (37.20%)                           | 0.85         |
| ALT (U/L), highest measured\(^e\) | 17 (7–375)                               | 18 (6–111)                            | 0.93         |
| ALT > 31 U/L                      | 2 (25%)                                  | 10 (22.72%)                           | 0.88         |
| LDH (U/L), highest measured\(^f\) | 588.5 (447—892)                        | 526 (350—1288)                       | 0.65         |
| LDH > 600 U/L                     | 3 (50%)                                  | 17 (40.47%)                           | 0.65         |
| CRP (mg/dL), highest measured\(^g\) | 16.5                                    | 9.25 (1.43—21.72)                    | 0.50         |
| Creatinine (mg/dL), highest measured\(^h\) | 0.58 (0.52–0.85)          | 0.52 (0.37–0.85)                     | 0.07         |

Values are presented as median (range) for continuous variables and as n(%) for categorical variables

**Abbreviations:** WBC White blood cells, INR International normalized ratio, AST Aspartate aminotransferase, ALT Alanine aminotransferase, LDH Lactate dehydrogenase, CRP C-reactive protein

\(^a\) Complete blood count data were available for only 56 women in the recovered group

\(^b\) Data were available for 9 women in the recovered group and 42 women in the active-infection group

\(^c\) Data were available for 18 women in the recovered group and 72 women in the active-infection group

\(^d\) Data were available for 6 women in the recovered group and 43 in the active-infection group

\(^e\) Data were available for 8 patients in the recovered group and 44 in the active-infection group

\(^f\) Data were available for 6 women in the recovered group and 42 in the active-infection group

\(^g\) Data were available for one woman on the recovered group and 12 women in the active-infection group

\(^h\) Data were available for 7 women in the recovered group and 45 in the active-infection group
adverse maternal, obstetrical, or perinatal outcomes with the exception of higher rates of postpartum treatment and of SARS-CoV-2-positive neonates in the active-infection group. Women in the active infection-group showed a trend of higher rates of severe and critical COVID-19 disease, ICU admission, mechanical ventilation, preterm delivery, and emergent caesarean deliveries mostly related to COVID-19 severity (and not for obstetrical indications).

Although the two groups had similar baseline characteristics, their COVID-19 features differed. The active-infection group was composed mostly of asymptomatic women who were diagnosed on routine screening at hospital admission whereas a large proportion of the recovered group had sought medical care for symptoms. However, by the time of delivery, the recovered group was completely asymptomatic whereas 5 women in the active-infection group had severe disease, including 3 (3.6%) with critical disease requiring ICU admission. Overall, the rate of caesarean delivery was very high [15] in the active-infection group, reaching 26.19%, and nearly half these procedures (40.9%) were performed for non-elective indications. By comparison, 17.39% of the recovered group underwent cesarean delivery, and about one-fourth of the procedures (26.2%) were for non-elective indications. The 3 patients in the active-infection group who required treatment in the ICU accounted for about one-fourth of the patients who had a cesarean delivery – which was performed so they could undergo more aggressive treatment for the disease, including prone positioning and ECMO. Thus, it is clear that the severity of disease dictated the mode of delivery. Similarly, three out of seven (42.85%) preterm births in the active infection group were iatrogenic and only induced in order to allow more treatment options for the maternal severe infection.

The WAPM study group reported an astoundingly high rate of 11.1% for ICU admissions in pregnant women with SARS-CoV-2 infection [5] and a meta-analysis by Allotey et al. [16] found that pregnant women with

| Table 4 Obstetric and neonatal outcomes in pregnant women with or without active disease at delivery |
|---------------------------------------------|-----------------|------------------|------------------|
| Outcome parameters                          | COVID-19 recovered patients | COVID-19 active patients | p-value |
|                                              | N = 92            | N = 84            |       |
| Mode of delivery                             |                  |                  | 0.35  |
| Normal vaginal                               | 73 (79.35%)      | 59 (70.24%)      |       |
| Assisted vaginal                             | 3 (3.26%)        | 3 (3.57%)        |       |
| Cesarean                                     | 16 (17.39%)      | 22 (26.19%)      |       |
| Indication for cesarean delivery             |                  |                  | 0.48  |
| Elective                                     | 12 (13.04%)      | 13 (15.47%)      |       |
| Non-elective                                 | 4 (4.34%)        | 9 (10.71%)       |       |
| COVID-19-related indications                 | 0 (0%)           | 4 (4.76%)        |       |
| Induction of labor                           |                  |                  | 0.71  |
| Gestational age at delivery (weeks)          | 39 (30–41)       | 39 (28–41)       |       |
| Preterm birth (< 37 weeks)                   | 10 (10.87%)      | 7 (8.33%)        |       |
| Length of hospitalization (days)             | 4 (2–40)         | 4 (2–60)         | 0.77  |
| Antepartum treatment                         | 2 (2.17%)        | 3 (3.57%)        |       |
| Postpartum treatment                         | 10 (10.87%)      | 64 (76.19%)      | <0.001|
| Neonatal gender, male                        | 46 (50%)         | 31 (36.9%)       | 0.09  |
| Birthweight (grams)                          | 3162 (1250–4206) | 3214 (780–4082)  | 0.42  |
| Neonatal weight percentile (%)               | 53 (3–99)        | 56 (4–99)        | 0.53  |
| Small for gestational age                    | 8 (8.70%)        | 5 (5.95%)        | 0.57  |
| Large for gestational age                    | 11 (11.9%)       | 10 (11.90%)      | 1     |
| 1-min Apgar < 7                              | 1 (1.09%)        | 5 (5.95%)        | 0.10  |
| 5-min Apgar < 7                              | 1 (1.09%)        | 3 (3.57%)        | 0.35  |
| Cord pH                                      | 7.32 (6.98–7.52) | 7.3 (7.1–7.39)   | 0.12  |
| pH < 7.2                                     | 4 (4.35%)        | 2 (2.38%)        | 1     |
| NICU admission                                | 7 (7.61%)        | 8 (9.52%)        | 1     |
| SARS-CoV-2-positive neonate                  | 0 (0%)           | 6 (7.14%)        | <0.001|

Values are presented as median (range) for continuous variables and as n(%) for categorical variables.

Abbreviations: NICU Neonatal intensive care unit.
COVID-19 had twice the likelihood of being admitted to the ICU than COVID-19-positive non-pregnant women. Our finding that none of the women in the recovered group were admitted to the ICU supports the notion that at the time of delivery, this group resembled the general pregnant population. This assumption is supported by the finding that rates of caesarean and preterm delivery were lower in the recovered group (17.39% and 10.87%, respectively) than in patients with COVID-19 reported in the literature (33%-91% and 12%-21%, respectively) [9, 17, 18], and were closer to the values reported in the general population (19.1% and 10.6%, respectively) [19, 20]. The majority of these women had full-term deliveries and were hospitalized for a short term thereafter; those hospitalized longer had obstetric indications unrelated to COVID-19.

We expected that women with COVID-19, even with mild to moderate disease, might be more likely to undergo induction of labor at term because of concerns about disease aggravation. Nevertheless, we found no between-group difference for this parameter. This might be explained by the large proportion of women in the active-infection group who were asymptomatic on presentation to the obstetric emergency room in active labor and were diagnosed only on routine screening according to hospital policy. Therefore, they did not require induction of labor in any case.

Of note, our results show that almost half the women in the recovered group were symptomatic, while the majority of women in the active infection group were asymptomatic. Bearing in mind that symptomatic disease is described as a possible marker for higher risk of perinatal complications [21], it is interesting that our study suggests otherwise.

Parturients with COVID-19, regardless of the status of the infection or severity of the disease, give birth in an isolated delivery room, usually unescorted by a family member. This experience can be difficult, especially for nulliparous women, and might potentially affect the postpartum period. From the caregiver aspect, the physical distancing from the patient along with the logistics required to enter the delivery room and perform the examination, may plausibly lead to unfavourable obstetric outcomes.

Analysis of neonatal parameters yielded no significant differences in median birthweight, birthweight percentile, and proportion of SGA neonates. Rates of SGA were low: 5.95% in the active-infection group and 8.75 in the recovered group. Accordingly, Mullins et al. [22] showed that SGA rates in pregnancies complicated by COVID-19 were comparable to those in in pre-COVID-19 registries.

The 7.4% rate of SARS-CoV-2-positive neonates in the active infection group was higher than the reported 2.5% overall risk of neonatal infection in women with symptomatic disease [23]. This findings can be explained by our screening routine which identifies asymptomatic patients, who are as infectious as their symptomatic counterparts [24]. Additionally, several studies suggested that neonatal infection rates may be higher in women with symptomatic COVID-19 [25–27], possibly because of the higher viral load and longer virus-shedding period which could contribute to viral transmission from mother to newborn [28]. It should also be noted that in our cohort, the majority of neonates born to recovered mothers were not tested for SARS-CoV-2, and those that were tested were frequently only swabbed once. By contrast, all neonates born to actively infected mothers were tested twice, 24 and 48 h after delivery. Therefore, some SARS-CoV-2-positive neonates in the recovered group may have been missed, especially those neonates born to women with a recent infection.

Strengths and limitations
The main strengths of this study are the methodology and setting. To the best of our knowledge, there are no prior studies comparing women with active COVID-19 at the time of delivery with women who had recovered from the infection. Furthermore, as all pregnant women who are hospitalized at our institution are routinely screened for SARS-CoV-2, the active infection group is representative of the spectrum of disease severity in this population. The recovered group, on the other hand, consisted of women who were infected at any time during pregnancy, and was therefore relatively heterogenic group.

The main limitation of this study is its retrospective design. It was especially challenging to collect data regarding COVID-19 symptoms in the recovered group owing to the risk of recall bias. Additionally, it is possible that our study was underpowered by the small patient groups. Further larger scale studies are needed to corroborate our findings.

Conclusion
We did not find a statistically significant difference between pregnant patients with an active SARS-CoV-2 infection at delivery and recovered COVID-19 pregnant women in terms of obstetric and perinatal complications. These findings suggest that labor and delivery is safe in women with an active SARS-CoV-2 infection. However, the women with an active infection showed a trend to more severe and critical COVID-19 disease, higher rates of ICU admission and mechanical ventilation, and a higher rate of cesarean delivery, especially caesarean delivery for non-elective, COVID-related indications.
Acknowledgements
The authors would like to thank the doctors at the Helen Schneider Hospital for Women for their assistance in acquiring data for this study.

Authors’ contributions
RZ and SD conceptualized the study, collected the data and performed the analysis, interpreted the data and drafted the manuscript; CJ collected the data; AS, SBH and RC revised the manuscript; AW conceptualized the study; EH conceptualized the study, interpreted the data and revised the manuscript; All authors read and approved the final manuscript.

Funding
The authors received no funding for conduction of this study.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study was approved by the Institutional Review Board of Rabin Medical Center (approval no. 331–20-RMC). Informed consent was waived due to the study’s retrospective design by the Institutional Review Board of Rabin Medical Center. I confirm that all methods were carried out in accordance with all relevant guidelines and regulations.

Consent for publication
There are no details, images, or videos relating to an individual person that require consent of publication in this manuscript.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Helen Schneider Hospital for Women, Rabin Medical Center – Beilinson Hospital, 39 Jabotinsky St., Petach Tikva, Israel. 2 Sackler Faculty of Medicine, Tel Aviv University, 4941492 Tel Aviv, Israel.

Received: 12 September 2021 Accepted: 6 June 2022
Published online: 23 June 2022

References
1. Rothan HA, Byarugady SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autonomm. 2020;109:1–2433.
2. Israel: WHO Coronavirus Disease (COVID‑19) Dashboard | WHO Coronavirus Disease (COVID‑19) Dashboard. https://covid19.who.int/region/euro/country/IL Accessed March 14, 2021.
3. Centers for Disease Control and Prevention. Pregnancy, Breastfeeding, or Caring for Newborns (Online). https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/pregnancy-breastfeeding.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fhcp%2Fpregnant-womenfaq.html. Accessed May 14, 2020.
4. Wastenedt EAN, Reynolds RM, van Boeckel SR, et al. Pregnancy and COVID-19. Physiol Rev. 2021;101:303–18.
5. Wong SF, Chow KM, Leung TN, et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol. 2004;191:292–7.
6. WAPM (World Association of Perinatal Medicine) Working Group on COVID-19. Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection. Ultrasound Obstet Gynecol. 2021;57:232–41.
7. Di Mascio D, Khalil A, Saccoone G, et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol. 2020;202:100107.
8. Altamora MC, Paredes T, Caceres D, Webb CM, Valdez LM, La Rosa M. Severe COVID-19 during pregnancy and possible vertical transmission. Am J Perinatol. 2020;37:861–5.
9. Mendoza M, Garcia-Ruiz I, Maiz N, et al. Pre-eclampsia-like syndrome induced by severe COVID-19: a prospective observational study. BJOG. 2020;127:1374–80.
10. Dubey P, Reddy SY, Manuel S, Dwivedi AK. Maternal and neonatal characteristics and outcomes among COVID-19 infected women: an updated systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2020;252:490–501.
11. Fan C, Guo Y, Qu P, et al. No obviously adverse pregnancy complications and outcomes of the recovered pregnant women from COVID-19. Reprod Toxicol. 2021;100:163–6.
12. COVID-19 recovery. (n.d.). https://www.govil/en/departments/general/corona-recovered-patients Accessed March 15, 2021.
13. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–42.
14. Dollberg S, Hakli Z, Mimouni FB, Gorlein I, Gordon ES. Birthweight standards in the live-born population in Israel. Isr Med Assoc J. 2005;7:311–4.
15. Pierce-Williams RAM, Burd J, Felder L, et al. Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: a United States cohort study. Am J Obstet Gynecol MFM. 2020;2:100134.
16. Allooty J, Stallings E, Bonet M, for PregCOV-19 Living Systematic Review Consortium, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320.
17. Delahoy MJ, Whitaker M, O’Halloran A, COVID-NET Surveillance Team, et al. Characteristics and Maternal and Birth Outcomes of Hospitalized Pregnant Women with Laboratory-Confirmed COVID-19 – COVID-NET, 13 States, March 1-August 22, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1347–54.
18. Moore KM, Suther MS. Comprehensive analysis of COVID-19 during pregnancy. Biochem Biophys Res Commun. 2021;538:180–6.
19. Chen I, Opiyo N, Tavender E, et al. Non-clinical interventions for reducing unnecessary caesarean section. Cochrane Database Syst Rev. 2018;9:CD005528.
20. Chawanpaiboon S, Vogel JP, Moller AB, et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. Lancet Glob Health. 2019;7:e37–46.
21. Metz TD, Clifton RG, Hughes BL, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network, et al. Disease severity and perinatal outcomes of pregnant patients with coronavirus disease 2019 (COVID-19). Obstet Gynecol. 2021;137:571–80.
22. Mullins E, Hudak ML, Banerjee J, PAN-COVID investigators and the National Perinatal COVID-19 Registry Study Group, et al. Pregnancy and neonatal outcomes of COVID-19: coexistence of common outcomes from PAN-COVID and AAP-SONFM registries. Ultrasound Obstet Gynecol. 2021;57:573–81.
23. Knight M, Bunch K, Voussden N, UK Obstetric Surveillance System SARS-CoV-2 Infection in Pregnancy Collaborative Group, et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. BMJ. 2020;369:m2107.
24. Gao Z, Xu Y, Sun C, et al. A systematic review of asymptomatic infections with COVID-19. J Microbiol Immunol Infect. 2021;54:12–6.
25. Lopian M, Kashani-Ligumsky L, Czeiger S, et al. Safety of vaginal delivery induced by severe COVID-19: a prospective observational study. BJOG. 2021;128:931–8.
26. Vivanti AJ, Vauloup-Fellous C, Prevot S, et al. Transplacental transmission of SARS-CoV-2 Infection in Pregnancy Collaborative Group, et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. BJM. 2020;369:m2107.
27. Knight M, Bunch K, Voussden N, UK Obstetric Surveillance System SARS-CoV-2 Infection in Pregnancy Collaborative Group, et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. BJM. 2020;369:m2107.
28. Gao Z, Xu Y, Sun C, et al. A systematic review of asymptomatic infections with COVID-19. J Microbiol Immunol Infect. 2021;54:12–6.
29. Lopian M, Kashani-Ligumsky L, Czeiger S, et al. Safety of vaginal delivery induced by severe COVID-19: a prospective observational study. BJOG. 2021;128:931–8.
30. Vivanti AJ, Vauloup-Fellous C, Prevot S, et al. Transplacental transmission of SARS-CoV-2 Infection in Pregnancy Collaborative Group, et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. BJM. 2020;369:m2107.
31. Knight M, Bunch K, Voussden N, UK Obstetric Surveillance System SARS-CoV-2 Infection in Pregnancy Collaborative Group, et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. BJM. 2020;369:m2107.
32. Gao Z, Xu Y, Sun C, et al. A systematic review of asymptomatic infections with COVID-19. J Microbiol Immunol Infect. 2021;54:12–6.